Sunday, 17 October 2021

Chime Biologics completes US$190M Series A+ financing to accelerate capacity expansion

26 March 2021 | News

Chime Biologics has built the world's first GE KuBio modular bio-manufacturing facility in Wuhan Bio-Lake Biotech Industry Development Zone of China

Photo Credit: PRNewswire

Photo Credit: PRNewswire

Chime Biologics, a China-based, world-class CDMO company, announced that it has secured a total commitment of US$190 million investment from institutional investors, and over $100 million investment has already been closed. This round of financing was led by VMS Group, followed by Fidelity International and Panacea Venture. Previously Chime Biologics had just completed its Series A round financing of US$125 million in early 2020.

Chime Biologics has built the world's first GE KuBio modular bio-manufacturing facility in Wuhan Bio-Lake Biotech Industry Development Zone of China (China Optics Valley). The facility complies with global quality standards of ICH, FDA, EMA and NMPA. With its state-of-the-art facility and rich experience in bio-manufacturing, Chime Biologics provides one-stop integrated solutions to support the dynamic needs of the rapidly evolving bio-pharmaceutical industry from early drug development to late stage clinical and commercial cGMP production. Since 2016 Chime Biologics has been maintaining a success rate of 100% in bio-manufacturing and providing various customers with top-quality biopharmaceutical products.

In order to meet the increasing demands for CDMO services from various customers, Chime Biologics has already started the second phase of its facility expansion to increase the total manufacturing capacity to more than 140,000L within the next 5 years.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account